Evidence map›Paper›PMID 41042333›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

Dual-tracer PET/CT with [

Jinhui Yang, Yujia Li, Yongxiang Tang, Bei Chen, Ling Xiao, Axel Rominger, Kuangyu Shi, Ming Zhou, Jian Li, Yi Cai and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05073653 (A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05073653 naunknown statusnot on this map

A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer

TypeinterventionalSponsorXiangya Hospital of Central South UniversityRan2021 to 2022Enrolled80ConditionsProstate CancerArms68Ga-PSMA PET/CT, 68Ga-GRP PET/CT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinhui Yang *Department of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Yujia Li *Department of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.ORCID 0009-0006-1633-463X
Yongxiang TangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Bei ChenDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Ling XiaoDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Ming ZhouDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Jian LiDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Yi Cai *Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, Xiangya Hospital, Central South University, Changsha, Hunan, China. cai-yi@csu.edu.cn.
Tao Jiang *Department of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. taojdream@hotmail.com.
Shuo Hu *Department of Nuclear Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. hushuo2018@163.com.ORCID 0000-0003-0998-8943

Funding

Hunan Provincial Science Fund for Distinguished Young Scholars 2024JJ2094Key Program of Ministry of Industry and Information Technology of China Technology of China CEIEC-2022-ZM02-0219National Natural Science Foundation of China 81801740National Natural Science Foundation of China 82272045
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA) and Gastrin-releasing peptide receptor (GRPR) PET demonstrate hopeful results in initial staging of prostate cancer (PCa), offering potential to support precision treatment decisions. We investigated whether the dual-tracer PET/CT with [

methods102 patients from prospective cohort NCT05073653 underwent preoperative [

results52 patients (51.0%) experienced BCR within the follow-up (median, 22.3 months). High PSMA-SUVmax (> 6.6) was associated with shorter BRFS (hazard ratio [HR] 3.17, p = 0.004), as was low GRPR-SUVmax (≤ 13.0) (HR 0.51, p = 0.026). Both were identified as independent predictors for BRFS. PSMA-SUVmax correlated with most of conventional clinicopathological factors (p < 0.005), whereas GRPR-SUVmax did not (p > 0.200). The combined PSMA + GRPR-SUVmax model achieved a superior time-dependent AUC of 0.73, compared with PSMA (AUC 0.63) or GRPR alone (AUC 0.62). External transcriptomic analysis corroborated that PSMA

conclusionThis study provides first clinical evidence that [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesProstate-Specific AntigenRadiopharmaceuticalsDipeptidesGallium RadioisotopesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617RadiopharmaceuticalsBiochemical recurrence-free survivalGRPRProstate cancerPSMA

Identifiers

PMID41042333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.